FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:496-507 February 2, 2006 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Slide Presentation Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Positron-emission tomography (PET) is a noninvasive imaging technique that exploits the unique decay physics of positron-emitting isotopes. The isotopes of oxygen, carbon, nitrogen, and fluorine have been used in the development of diagnostically useful biologic compounds that are available for PET imaging in order to provide a functional or metabolic assessment of normal tissues or disease conditions.

The past few years have seen a tremendous expansion of clinical applications of PET, particularly in oncology, mostly with the use of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) as the PET tracer. PET with ¹⁸F-FDG is now being used in the evaluation of several neoplasms, both . . . [Full Text of this Article]

Oncologic PET Tracers

PET vs. Conventional Radiologic Imaging

Applications in Assessment of Cancer after Therapy

Monitoring Response to Treatment

Restaging

Requirement for Pretreatment PET before Restaging PET

Appropriate Time Point for Restaging with PET

Viable Tumor vs. Necrosis or Fibrosis in Residual Masses

Detection of Recurrence in Asymptomatic Patients

False Positive Findings on Restaging with PET

Effect of Restaging with PET on Quality of Life in Cancer

Cost-Effectiveness of Restaging with PET

Radiation Dose from PET Scans

Conclusions

Source Information

From the Department of Radiology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City (M.E.J.); and the Division of Hematology–Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, D.C. (B.D.C.).

A slide presentation is available with the full text of this article at www.nejm.org. The slides show multiple examples of the uses of PET in clinical oncology.

Address reprint requests to Dr. Juweid at the University of Iowa, Department of Radiology, JPP 3859, 200 Hawkins Dr., Iowa City, IA 52242; or at malik-juweid@uiowa.edu.

Related Letters:

Positron-Emission Tomography in Cancer Therapy
Meyer M. A., Aliberti S., Grignani G., Aglietta M., Juweid M. E., Cheson B. D.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1958-1960, May 4, 2006. Correspondence

This article has been cited by other articles:

• Souza, M. J., Newman, S. J., Greenacre, C. B., Avenell, J. S., Wall, J. S., Phillips, J. C., Fry, M. M., Donnell, R. L., Daniel, G. B. (2008). Diffuse intestinal T-cell lymphosarcoma in a yellow-naped Amazon parrot (Amazona ochrocephala auropalliata). jvdi 20: 656-660 [Abstract] [Full Text]  
• Emmering, J., Krak, N. C., Van der Hoeven, J. J. M., Spreeuwenberg, M. D., Twisk, J. W. R., Meijer, S., Pinedo, H. M., Hoekstra, O. S. (2008). Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol 19: 1573-1577 [Abstract] [Full Text]  
• Chee, K. G., Nguyen, D. V., Brown, M., Gandara, D. R., Wun, T., Lara, P. N. Jr (2008). Positron Emission Tomography and Improved Survival in Patients With Lung Cancer: The Will Rogers Phenomenon Revisited. Arch Intern Med 168: 1541-1549 [Abstract] [Full Text]  
• Benz, M. R., Evilevitch, V., Allen-Auerbach, M. S., Eilber, F. C., Phelps, M. E., Czernin, J., Weber, W. A. (2008). Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors. JNM 49: 1038-1046 [Abstract] [Full Text]  
• Mohile, N. A., DeAngelis, L. M., Abrey, L. E. (2008). The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 10: 223-228 [Abstract] [Full Text]  
• Ueda, S., Tsuda, H., Asakawa, H., Shigekawa, T., Fukatsu, K., Kondo, N., Yamamoto, M., Hama, Y., Tamura, K., Ishida, J., Abe, Y., Mochizuki, H. (2008). Clinicopathological and Prognostic Relevance of Uptake Level using 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging (18F-FDG PET/CT) in Primary Breast Cancer. Jpn J Clin Oncol 38: 250-258 [Abstract] [Full Text]  
• Evilevitch, V., Weber, W. A., Tap, W. D., Allen-Auerbach, M., Chow, K., Nelson, S. D., Eilber, F. R., Eckardt, J. J., Elashoff, R. M., Phelps, M. E., Czernin, J., Eilber, F. C. (2008). Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas. Clin. Cancer Res. 14: 715-720 [Abstract] [Full Text]  
• Juweid, M. E. (2008). 18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?. JNM 49: 9-12 [Full Text]  
• Boss, D. S., Olmos, R. V., Sinaasappel, M., Beijnen, J. H., Schellens, J. H. M. (2008). Application of PET/CT in the Development of Novel Anticancer Drugs. The Oncologist 13: 25-38 [Abstract] [Full Text]  
• Oudoux, A., Salaun, P.-Y., Bournaud, C., Campion, L., Ansquer, C., Rousseau, C., Bardet, S., Borson-Chazot, F., Vuillez, J.-P., Murat, A., Mirallie, E., Barbet, J., Goldenberg, D. M., Chatal, J.-F., Kraeber-Bodere, F. (2007). Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. J. Clin. Endocrinol. Metab. 92: 4590-4597 [Abstract] [Full Text]  
• Schwarz, J. K., Siegel, B. A., Dehdashti, F., Grigsby, P. W. (2007). Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma. JAMA 298: 2289-2295 [Abstract] [Full Text]  
• Ceresoli, G. L., Chiti, A., Santoro, A. (2007). 11C-Labeled Methionine and Evaluation of Malignant Pleural Mesothelioma. NEJM 357: 1982-1984 [Full Text]  
• Herbertson, R. A., Lee, S. T., Tebbutt, N., Scott, A. M. (2007). The expanding role of PET technology in the management of patients with colorectal cancer. Ann Oncol 18: 1774-1781 [Abstract] [Full Text]  
• de Geus-Oei, L.-F., van der Heijden, H. F.M., Visser, E. P., Hermsen, R., van Hoorn, B. A., Timmer-Bonte, J. N.H., Willemsen, A. T., Pruim, J., Corstens, F. H.M., Krabbe, P. F.M., Oyen, W. J.G. (2007). Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer. JNM 48: 1592-1598 [Abstract] [Full Text]  
• Jaffer, F. A., Libby, P., Weissleder, R. (2007). Molecular Imaging of Cardiovascular Disease. Circulation 116: 1052-1061 [Full Text]  
• Du, Y., Cullum, I., Illidge, T. M., Ell, P. J. (2007). Fusion of Metabolic Function and Morphology: Sequential [18F]Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Studies Yield New Insights Into the Natural History of Bone Metastases in Breast Cancer. JCO 25: 3440-3447 [Abstract] [Full Text]  
• Engert, A., Franklin, J., Eich, H. T., Brillant, C., Sehlen, S., Cartoni, C., Herrmann, R., Pfreundschuh, M., Sieber, M., Tesch, H., Franke, A., Koch, P., de Wit, M., Paulus, U., Hasenclever, D., Loeffler, M., Muller, R.-P., Muller-Hermelink, H. K., Duhmke, E., Diehl, V. (2007). Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial. JCO 25: 3495-3502 [Abstract] [Full Text]  
• Kong, F.-M. S., Frey, K. A., Quint, L. E., Haken, R. K. T., Hayman, J. A., Kessler, M., Chetty, I. J., Normolle, D., Eisbruch, A., Lawrence, T. S. (2007). A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non Small-Cell Lung Cancer. JCO 25: 3116-3123 [Abstract] [Full Text]  
• Kim, Y. H., Willemze, R., Pimpinelli, N., Whittaker, S., Olsen, E. A., Ranki, A., Dummer, R., Hoppe, R. T., for the ISCL and the EORTC, (2007). TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110: 479-484 [Abstract] [Full Text]  
• Torigian, D. A., Huang, S. S., Houseni, M., Alavi, A. (2007). Functional Imaging of Cancer with Emphasis on Molecular Techniques. CA Cancer J Clin 57: 206-224 [Abstract] [Full Text]  
• Herrmann, K., Wieder, H. A., Buck, A. K., Schoffel, M., Krause, B.-J., Fend, F., Schuster, T., Meyer zum Buschenfelde, C., Wester, H.-J., Duyster, J., Peschel, C., Schwaiger, M., Dechow, T. (2007). Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma. Clin. Cancer Res. 13: 3552-3558 [Abstract] [Full Text]  
• Kim, J. M., Ryu, J.-S., Kim, T. Y., Kim, W. B., Kwon, G. Y., Gong, G., Moon, D. H., Kim, S. C., Hong, S. J., Shong, Y. K. (2007). 18F-Fluorodeoxyglucose Positron Emission Tomography Does Not Predict Malignancy in Thyroid Nodules Cytologically Diagnosed as Follicular Neoplasm. J. Clin. Endocrinol. Metab. 92: 1630-1634 [Abstract] [Full Text]  
• Tan, A., Adelstein, D. J., Rybicki, L. A., Saxton, J. P., Esclamado, R. M., Wood, B. G., Lorenz, R. R., Strome, M., Carroll, M. A. (2007). Ability of Positron Emission Tomography to Detect Residual Neck Node Disease in Patients With Head and Neck Squamous Cell Carcinoma After Definitive Chemoradiotherapy. Arch Otolaryngol Head Neck Surg 133: 435-440 [Abstract] [Full Text]  
• Clavien, P.-A., Petrowsky, H., DeOliveira, M. L., Graf, R. (2007). Strategies for Safer Liver Surgery and Partial Liver Transplantation. NEJM 356: 1545-1559 [Full Text]  
• Strobel, K, Schaefer, N., Renner, C, Veit-Haibach, P, Husarik, D, Koma, A., Hany, T. (2007). Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?. Ann Oncol 18: 658-664 [Abstract] [Full Text]  
• Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R. J., Weber, W. A., Reske, S. N., Schwaiger, M., Schwartz, L. H., Zijlstra, J. M., Siegel, B. A., Cheson, B. D. (2007). Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. JCO 25: 571-578 [Abstract] [Full Text]  
• Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., Rosen, S. T., Stroobants, S., Lister, T. A., Hoppe, R. T., Dreyling, M., Tobinai, K., Vose, J. M., Connors, J. M., Federico, M., Diehl, V. (2007). Revised Response Criteria for Malignant Lymphoma. JCO 25: 579-586 [Abstract] [Full Text]  
• Jentzen, W., Freudenberg, L., Eising, E. G., Heinze, M., Brandau, W., Bockisch, A. (2007). Segmentation of PET Volumes by Iterative Image Thresholding. JNM 48: 108-114 [Abstract] [Full Text]  
• Weber, W. A., Figlin, R. (2007). Monitoring Cancer Treatment with PET/CT: Does It Make a Difference?. JNM 48: 36S-44S [Abstract] [Full Text]  
• Detsky, A. S. (2006). Sources of bias for authors of clinical practice guidelines.. CMAJ 175: 1033- 1035 [Full Text]  
• Detsky, A. S. (2006). Sources de partialite chez les auteurs de guides de pratique clinique. CMAJ 175: 1035-1035 [Full Text]  
• Ceresoli, G. L., Chiti, A., Zucali, P. A., Rodari, M., Lutman, R. F., Salamina, S., Incarbone, M., Alloisio, M., Santoro, A. (2006). Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose. JCO 24: 4587-4593 [Abstract] [Full Text]  
• Iglehart, J. K. (2006). The new era of medical imaging--progress and pitfalls.. NEJM 354: 2822-2828 [Full Text]  
• Weissleder, R. (2006). Molecular imaging in cancer.. Science 312: 1168-1171 [Abstract] [Full Text]  
• Meyer, M. A., Aliberti, S., Grignani, G., Aglietta, M., Juweid, M. E., Cheson, B. D. (2006). Positron-emission tomography in cancer therapy.. NEJM 354: 1958-1960 [Full Text]  
• Newman, L. A. (2006). The Search for Occult Metastatic Disease in Breast Cancer Patients: How Far Should We Go?. Ann. Surg. Oncol. 13: 604-606 [Full Text]  
• Juweid, M. E. (2006). Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma. ASH Education Book 2006: 259-265 [Abstract] [Full Text]